Home NEWS AND MEDIA

NEWS AND MEDIA

Jul 2026

NeuExcell's NXL-004 Achieves 100% One-Year Survival in High-Dose Cohort for Recurrent Malignant Glioma

Learn more
May 2026

NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO

Learn more
Dec 2025

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma

Learn more
Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease

Learn more
Mar 2025

NeuExcell Therapeutics Initiates First-in-Human Clinical Trial of NXL-001 to Treat Alzheimer's Disease

Learn more